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Aim To determine the effects of metformin or liraglutide on 
oxidative stress level and antioxidative enzymes gene ex-
pression and activity in the blood and vessels of pre-diabet-
ic obese elderly Sprague-Dawley (SD) rats of both sexes.
Methods Male and female SD rats were assigned to the 
following groups: a) control group (fed with standard ro-
dent chow); b) high-fat and high-carbohydrate diet 
(HSHFD) group fed with HSHFD from 20-65 weeks of age; 
c) HSHFD+metformin treatment (50 mg/kg/d s.c.); and d) 
HSHFD+liraglutide treatment (0.3 mg/kg/d s.c). Oxidative 
stress parameters (ferric reducing ability of plasma and 
thiobarbituric acid reactive substances) and superoxide dis-
mutase (SOD), catalase (CAT), and glutathione peroxidase 
(GPx) activity and gene expression were determined from 
serum, aortas, and surface brain blood vessels (BBV).
Results HSHFD increased body weight in both sexes com-
pared with the control group, while liraglutide prevented 
this increase. Blood glucose level did not change. The lira-
glutide group had a significantly increased antioxidative ca-
pacity compared with the HSHFD group in both sexes. The 
changes in antioxidative enzymes’ activities in plasma were 
more pronounced in male groups. The changes in gene ex-
pression of antioxidative enzymes were more prominent in 
microvessels and may be attributed to weight gain preven-
tion.
Conclusions Obesity and antidiabetic drugs caused sex-
related differences in the level of antioxidative parameters. 
Liraglutide exhibited stronger antioxidative effects than 
metformin. These results indicate that weight gain due to 
HSHFD is crucial for developing oxidative stress and for in-
hibiting antioxidative protective mechanisms.
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Lifestyle and diet changes are related to the development 
of many chronic cardiometabolic diseases, such as obesi-
ty, type 2 diabetes mellitus (T2DM), cardiovascular disease 
(CVD), and atherosclerosis (1-3). Their common denomina-
tor is oxidative stress (4), an imbalance between the pro-
duction of reactive oxygen species (ROS; such as super-
oxide, hydrogen peroxide, etc) and antioxidative capacity 
(5). Oxidative stress is caused by different types of chronic 
or acute dietary protocols, such as high-fat-high-carbohy-
drate diet (HSHFD) or high dietary intake of saturated fatty 
acids and trans-fatty acids, via multiple biochemical mech-
anisms (6-8). The high level of free radicals is decreased 
through a synergistical action of antioxidant enzymes (su-
peroxide dismutases [SOD], glutathione peroxidases [GPx], 
catalase [CAT], glutathione S-transferase, thioredoxin re-
ductase, etc) (9). Antioxidant status in blood vessel tissue 
and blood samples can help us assess the impact of obe-
sity and T2DM on the cardiovascular system. For example, 
the activity of antioxidative enzymes in obese individuals 
is lower than that of non-obese individuals, and probably 
underlies the obesity-related health problems (10). Besides 
T2DM, obesity is often accompanied by an increased risk 
of CVD, including coronary artery disease, stroke, and pe-
ripheral arterial disease (11). All of these diseases present 
with endothelial dysfunction due to a reduced bioavail-
ability of vasodilator nitric oxide, inflammation, increased 
free radicals and cytokines production, and oxidation of 
low-density lipoproteins (12,13). In addition, obesity and 
T2DM are often associated with hyperinsulinemia, a condi-
tion characterized by a glucose transport disorder, pancre-
atic β-cell dysfunction, increased levels of oxidative stress, 
and inflammation (14,15).
Liraglutide, a glucagon-like peptide-1 agonist (GLP-1), de-
creases blood glucose by potentiating glucose-dependent 
insulin secretion, by enhancing β-cells growth, and by re-
ducing food intake and body weight (16). One of its ef-
fects is also the reduction of the plasma ROS level in T2DM 
patients (17). Liraglutide decreases oxidative stress in dia-
betes by the activation of cAMP, epidermal growth factor 
receptor-PI3K, and protein kinase C pathways, and Nrf-2 
activation. These processes increase the antioxidant capac-
ity or antioxidative enzymes expression in tissues, the pa-
rameters that are often altered in diabetes (18,19). Animal 
studies showed liraglutide to improve insulin resistance in 
the liver and adipose tissue of diabetic mice (20) and to af-
fect vasculature by increasing microvascular recruitment 
and blood flow (21). Furthermore, liraglutide induced car-
dioprotection and reduced death rates from cardiovas-
cular causes in T2DM (21).
Metformin mechanisms of action include improving insu-
lin sensitivity and reducing glycemia without significant-
ly increasing hypoglycemia event rate (22). Similar to lira-
glutide, metformin has antioxidant and anti-inflammatory 
properties (23). It reduces the expression of NF-kB, a tran-
scription factor involved in inflammation, by inhibiting IL-8 
and IL-1α inflammatory cytokines, and inhibits the differ-
entiation of monocytes into macrophages. It contributes 
to the reduction of oxidative stress by reducing hydrogen 
peroxide level by activating catalase or by reducing the 
transcription of NADPH oxidase 4 (23). Furthermore, like li-
raglutide, metformin has a protective effect on vasculature. 
For example, it can inhibit various steps of angiogenesis, 
including endothelial cell proliferation in retinal vascular 
endothelial cell culture, or reduce spontaneous intraretinal 
neovascularization (24).
This study, for the first time in the literature, assessed the 
gene expression of antioxidant enzymes (SOD, GPx, and 
CAT) in the aortas and surface brain blood vessels of 
obese animals of both sexes, and explored the effects of 




The sampling was performed at the Department of Phar-
macodynamics and Biopharmacy, Faculty of Pharmacy, 
University of Szeged, Hungary. All molecular measure-
ments were carried out in the Laboratory for Molecular and 
Clinical Immunology at the Department of Physiology and 
Immunology, Faculty of Medicine, and at the Laboratory 
for Biochemistry, Department of Biology, Josip Juraj Stross-
mayer University of Osijek. The study (including the feeding 
protocol, drug treatments, sampling, and sample process-
ing to final results) lasted from June 2015 until November 
2016. All experimental procedures conformed to the Eu-
ropean Communities Council Directives (2010/63/EU) and 
were approved by the Hungarian National Scientific Ethics 
Committee on Animal Experimentation (IV/3084/2016).
Experimental animals
Male and female Sprague-Dawley rats (Charles River, Ger-
many) were given rodent pellet diet and drinking water ad 
libitum. They were housed four rats per cage (polypropyl-
ene cages Type IV, floor area 1800 cm2) under controlled 
temperature (20-23 °C) in humidity- (40%-60%) and light- 
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(12 h light/dark regime) regulated rooms. Commercially 
available carbohydrate- and fat-rich food (56% of carbohy-
drates and 12% of crude fat) was purchased from Altromin 
Spezialfutter GmbH & Co (Lage, Germany).
Studied groups
The animals of both sexes were randomized into four 
groups. A total of 31 female and 32 male rats were included 
in the study. However, some animals did not survive until 
the end of the protocol, so the final number of animals was 
28 female and 29 male rats. The groups were as follows:
a) control group (initial: nfemale = 7; nmale = 8, final: nfemale = 6; 
nmale = 7) – animals were fed with standard rat chow during 
the whole protocol;
b) HSHFD group (initial: nfemale = 8; nmale = 8, final: nfemale = 8; 
nmale = 6) – carbohydrate- and fat-rich diet for 20 weeks, 
from the 45th week to 65th week of age;
c) HSHFD+metformin (initial: nfemale = 8; nmale = 8, final: nfe-
male = 7; nmale = 8) – carbohydrate- and fat-rich diet from the 
45th week of age + metformin treatment (50 mg/kg/d s.c.) 
from the 51st-65th week of age; and
d) HSHFD+liraglutide (initial: nfemale = 8; nmale = 8, final: nfe-
male = 7; nmale = 8) – carbohydrate- and fat-rich diet from the 
45th week of age + liraglutide treatment (0.3 mg/kg/d s. c.) 
from the 51st-65th week of age.
Metformin (Sigma Aldrich, Budapest, Hungary) and lira-
glutide (Creative Peptides INC, New York, NY, USA) were ad-
ministered each morning between 9.00 and 10.00 am. The 
drugs were dissolved in a special buffer containing 0.5 mg 
disodium hydrogen phosphate dihydrate, 4.7 mg propyl-
ene glycol, and 1.8 mg phenol in 1-mL water solution (pH 
8.5). The control group was treated with 0.1 mL buffer each 
day of treatment.
Sampling
The baseline body weight results represent the body 
weight of 45-week-old rats that received no treatment or 
HSHFD diet and were measured before sacrifice. Blood glu-
cose concentration was also measured before sacrifice at 8 
am with OneTouch® UltraMini® Glucose Meter (Milpitas, CA, 
USA), after a 16-hour fast. Blood was collected from the tail 
vein of awake, non-anesthetized rats that were put in a re-
strainer. At the end of the protocol, animals were anesthe-
tized with isoflurane (Forane® isofluranum, Abbott Labora-
tories Ltd, Queenborough, UK). Blood (serum and plasma) 
samples were collected for enzyme activity and oxidative 
stress measurements, while BBV and aortas were collected 
for gene expression measurements. Surface BBV were iso-
lated with forceps and dissection microscope and quick-
frozen in liquid nitrogen. Thoracic aortas were stored in the 
same fashion.
mRnA expression studies
Samples and total RNA were homogenized with One Step 
RNA Reagent (Bio Basic Inc, Markham, Canada) according 
to the manufacturer`s protocol. RNA was purified from 
gDNA with Deoxyribonuclease I kit (Sigma-Aldrich, St. Lou-
is, MO; USA), and the obtained cDNA was synthesized with 
High Capacity cDNA kit (Applied Biosystems, Waltham, 
MA, USA). RNA expression was determined with SsoFast 
EvaGreen Supermix (Bio Rad, Hercules, CA, USA). The fol-
lowing genes: Sod isoforms (Cu/Zn Sod, MnSod, EC-Sod), 
Gpx1 and Gpx4, and Cat were normalized to the expression 
of the housekeeping genes hypoxanthine-guanine phos-
phoribosyltransferase (Hprt) and 18s. The results obtained 
with 18s were more consistent, so this gene was used in 
further analysis. The gene expression analysis was per-
formed with BioRad CFX96 (25,26).
Antioxidant enzyme activities
Antioxidant enzyme activities were measured from plasma 
samples. All measurements were performed as previously 
described (25,27-29). The enzyme activities were expressed 
as units per milligram protein. Enzyme activity assay was 
performed with a Lambda 25UV-Vis spectrophotometer 
equipped with a UV WinLab 6.0 software package (Perki-
nElmer For the Better, Waltham, MA, USA). The protein con-
centration in the samples (mg/mL) was determined with 
Bradford reagent at 595 nm. Bovine serum albumin was 
used as a standard.
oxidative stress markers
Serum levels of an oxidative stress marker (thiobarbitu-
ric acid reactive substances; TBARS) and plasma antioxi-
dant capacity (ferric reducing ability of plasma; FRAP) were 
measured spectrophotometrically. TBARS was used for 
measuring the oxidative stress level, more precisely the 
products of lipid peroxidation with malondialdehyde 
as standard (μM/L MDA) at 572 nm and 532 nm. FRAP 
(mM/L Trolox) is a spectrophotometric method used 
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to determine the total amount of antioxidants in the sam-
ple, ie, their ability to reduce Fe3+ ion into the Fe2+ ion. Both 
methods have been described in detail previously (25-30). 
The values were obtained by Nanophotometer P300 UV 
(Implen GmbH, Schatzbogen, Germany).
Statistical analysis
The sample size was determined with the Sigma Plot v 11.0 
program (Systat Software, Inc. San Jose, CA, USA). To obtain 
the power of 0.8, p value less than 0.05, and the minimum 
expected difference of 0.25, at least 4 animals per group 
were required. The normality of distribution was assessed 
with the Shapiro Wilk test. All results were analyzed with 
a two-way ANOVA test, followed by a Bonferroni post hoc 
test, and data are presented as arithmetic means ± stan-
dard deviation. The level of significance was set at P < 0.05. 
The analysis was performed with GraphPad Prism 8.0.2 
(San Diego, CA, USA).
RESultS
Changes in body mass and blood glucose level
The average baseline weight of  female rats was 337.82 ± 3.80 
g and that of male rats was 556.31 ± 4.66 g. The results are 
presented as percent change of body weight (final body 
weight vs baseline body weight).
Animals of both sexes in the HSHFD group (20.87% female 
group, P < 0.05, and 16.88% of the male group, P < 0.001) 
and HSHFD+metformin group (19.53% of the female 
group, P < 0.05, and 12.05% of the male group, P < 0.01) ex-
hibited a significant increase in the percent change of body 
weight compared with the baseline (6.00% female group 
and 1.01% male group), which led to obesity development. 
Liraglutide treatment (2.23% female group and 5.16% 
male group) significantly reduced the percentage of body 
weight change in both sexes compared with the HSHFD 
group (20.87% of the female group, P < 0.01, and 16.88% of 
the male group, P < 0.001) and HSHFD+metformin group 
(19.53% of the female group, P < 0.01 and 12.05% of the 
male group, P < 0.01) (Figure 1). In neither of the sexes, sig-
nificant differences in glucose concentration were found 
at the end of the protocol (Figure 2).
mRnA gene expression in BBV (microcirculation) and 
aortas (macrocirculation)
The relative gene expression of Gpx1 (P < 0.01) and Gpx4 
(P < 0.05) was significantly increased in control male aortas 
compared with control female aortas. Cu/Zn Sod gene ex-
pression was significantly increased (P < 0.001) in control 
male BBV compared with control female BBV. MnSod gene 
expression was significantly increased in HSHFD male BBV 
compared with HSHFD female BBV (P < 0.05). GPx1 gene ex-
pression was significantly decreased in control male BBV 
FIGuRE 1. the percentage (%) of the body weight change at the end of the protocol compared with baseline values in female 
(A) and male (B) rats. Female groups (control n = 5, carbohydrate- and fat-rich diet [HSHFD] n = 4, HSHFD+metformin n = 4, 
HSHFD+liraglutide n = 5) and male groups (control n = 7, HSHFD n = 6, HSHFD+metformin n = 8, HSHFD+liraglutide n = 8). Data are 
presented as arithmetic mean ± standard deviation (SD) (two-way AnoVA P = 0.8852, F = 0.2153).
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compared with control female BBV (P < 0.001) (Table 1). 
Cu/Zn Sod expression was significantly increased in female 
aortas in the HSHFD+liraglutide group compared with the 
HSHFD and HSHFD+metformin groups (P < 0.05) and Cat 
gene expression compared with other groups (P < 0.001) 
(Table 2). EC-Sod (P < 0.05) and Gpx1 (P < 0.05) gene expres-
sion in male HSHFD+metformin group aortas was signifi-
cantly decreased compared with the control group. Gpx4 
gene expression in male HSHFD+metformin aortas was sig-
nificantly decreased compared with the HSHFD+liraglutide 
tABlE 2. Relative expression of superoxide dismutase isoforms (Cu/Zn Sod, Mn Sod, and EC Sod), glutathione peroxidase 1 and 4 
(Gpx1, Gpx4), and catalase (Cat) genes in female aortas. Data are presented as arithmetic mean ± SD (two-way AnoVA)
Female aortas Cu/Zn Sod* MnSod† EC-Sod‡ Gpx1§ Gpx4II Cat¶
Control 0.99 ± 0.63 (N = 4) 0.09 ± 0.36 (N = 5) 0.23 ± 0.25 (N = 5) 0.09 ± 0.05 (N = 5) 0.19 ± 0.20 (N = 5) 1.01 ± 0.79†† (N = 5)
Carbohydrate- and 
fat-rich diet (HSHFD)
0.61 ± 0.33** (N = 6) 0.09 ± 0.08 (N = 7) 0.15 ± 0.08 (N = 6) 0.08 ± 0.04 (N = 7) 0.19 ± 0.11 (N = 7) 0.84 ± 0.50†† (N = 5)
HSHFD+metformin 0.55 ± 0.64**(N = 6) 0.07 ± 0.06 (N = 5) 0.15 ± 0.23 (N = 6) 0.08 ± 0.07 (N = 6) 0.04 ± 0.02 (N = 6)1.12 ± 0.90†† (N = 7)
HSHFD+liraglutide 1.48 ± 0.33(N = 4) 0.30 ± 0.20 (N = 4) 0.70 ± 0.55 (N = 4) 0.24 ± 0.18 (N = 4) 0.14 ± 0.10 (N = 5) 13.99 ± 2.92 (N = 4)
*Cu/Zn Sod (P = 0.1026, F = 2.22).
†MnSod (P = 0.7179, F = 0.4513).
‡EC-Sod (P = 0.2289, F = 1.512).
§Gpx1 (P = 0.2512, F = 1.426).
IIGpx4 (P = 0.5166, F = 0.7716).
¶Cat(P < 0.0001, F = 78.42).
**HSHFD+liraglutide vs HSHFD; HSHFD+metformin (Cu/Zn Sod P < 0.05), Bonferroni post hoc test, P < 0.05.
††HSHFD+liraglutide vs HSHFD; HSHFD+metformin; control (Cat P < 0.05), Bonferroni post hoc test, P < 0.05.
tABlE 1. Antioxidant enzymes relative gene expression in female and male aortas and brain blood vessels (BBV). Results are presented as relative expres-
sion of gene normalized to hypoxanthine-guanine phosphoribosyltransferase as a reference gene and summarized as arithmetic mean ± standard devia-
tion (two-way AnoVA)
Cu/Zn Sod* MnSod† EC-Sod‡ Gpx1§ Gpx4iI Cat¶
Aortas female male female male female male female male female male female male
Control 0.99 ± 0.64 
(N = 4)
0.57 ± 0.62 
(N = 5)
0.21 ± 0.41 
(N = 5)
0.10 ± 0.09 
(N = 5)
0.23 ± 0.29 
(N = 5)
0.72 ± 0.80 
(N = 4)
0.09 ± 0.05 
(N = 5)
0.70 ± 0.52*** 
(N = 5)




1.01 ± 0.82 
(N = 5)






0.61 ± 0.34 
(N = 6)
0.34 ± 0.24 
(N = 6)
0.09 ± 0.08 
(N = 7)
0.08 ± 0.05 
(N = 5)
0.15 ± 0.08 
(N = 6)
0.37 ± 0.27 
(N = 5)
0.08 ± 0.04 
(N = 7)
0.2 ± 0.25 
(N = 5)
0.16 ± 0.12 
(N = 7)
0.56 ± 0.36 
(N = 6)
0.84 ± 0.51 
(N = 5)
0.56 ± 0.37 
(N = 4)
Cu/Zn Sod** MnSod†† EC-Sod‡‡ Gpx1§§ Gpx4II II Cat¶¶
BBV female male female male female male female male female male female male
Control 0.39 ± 0.13 
(N = 6)
0.80 ± 0.06††† 
(N = 5)
0.55 ± 0.20 
(N = 6)
0.46 ± 0.60 
(N = 5)
0.59 ± 0.34 
(N = 6)
1.13 ± 0.95 
(N = 5)
1.77 ± 0.71 
(N = 6)
0.73 ± 0.12††† 
(N = 5)
0.69 ± 0.47 
(N = 6)
0.75 ± 0.28 
(N = 5)
0.85 ± 0.27 
(N = 6)






0.21 ± 0.15 
(N = 6)
0.39 ± 0.13 
(N = 5)
0.02 ± 0.003 
(N = 4)
0.30 ± 0.16‡‡‡ 
(N = 6)
0.046 ± 0.04 
(N = 8)
0.14 ± 0.09 
(N = 5)
0.09 ± 0.09 
(N = 6)
0.39 ± 0.30 
(N = 6)
0.06 ± 0.03 
(N = 8)
0.17 ± 0.05 
(N = 5)




*Cu/Zn Sod (P = 0.7194, F = 0.1337).
†MnSod (P = 0.5165, F = 0.4379).
‡EC-Sod (P = 0.4627, F = 0.5662).
§Gpx1 (P = 0.0285, F = 5.673).
IIGpx4 (P = 0.5229, F = 0.4230)
¶Cat (P = 0.4006, F = 0.7485).
**Cu/Zn Sod (P = 0.0311, F = 5.471).
††MnSod (P = 0.0151, F = 7.300).
‡‡EC-Sod (P = 0.2579, F = 1.356).
§§Gpx1 (P = 0.0008, F = 15.98).
II IIGpx4 (P = 0.7992, F = 0.06643).
¶¶Cat(P = 0.1835, F = 1.933).
***Male aortas control vs female aortas control (Gpx1 P < 0.01; Gpx4 P < 0.05), Bonferroni post hoc test, P < 0.05.
†††Male BBV control vs female BBV control (Cu/Zn Sod P < 0.001; Gpx1 P < 0.05), Bonferroni post hoc test, P < 0.05.
‡‡‡Male BBV HSHFD vs female BBV HSHFD (MnSod P < 0.05), Bonferroni post hoc test, P < 0.05.
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group (P < 0.05). Gpx1 gene expression in HSHFD and 
HSHFD+metformin male aortas was significantly decreased 
compared with the control group (P < 0.05) (Table 3)
In female BBV, MnSod gene expression (P < 0.001) was sig-
nificantly decreased in all HSHFD groups (with or with-
out treatment), and EC-Sod (P < 0.05) and Gpx4 (P < 0.05) 
were decreased in the HSHFD and HSHFD+metformin 
groups compared with the control group. Metformin 
and liraglutide increased Gpx1 gene expression (P < 0.05) 
compared with the HSHFD group. Gpx4 gene expres-
sion in female BBV was significantly increased in the 
HSHFD+liraglutide group compared with the con-
trol (P < 0.05), HSHFD, and HSHFD+metformin groups 
(P < 0.001). Cat gene expression was significantly increased 
in the HSHFD+liraglutide group compared with the con-
trol group (P < 0.05) (Table 4).
Cu/Zn Sod gene expression in male BBV was significant-
ly decreased in the HSHFD group compared with other 
groups (P < 0.05). MnSod gene expression was significantly 
increased in the HSHFD+liraglutide group compared with 
the HSHFD and HSHFD+metformin groups (P < 0.01). Rela-
tive gene expression of EC-Sod and Gpx4 was significantly 
decreased in all HDHFD groups compared with controls 
(P < 0.05) (Table 5).
tABlE 4. Relative expression of superoxide dismutase isoforms Cu/Zn Sod, Mn Sod, and EC Sod), glutathione peroxidase 1 and 4 
(Gpx1, Gpx4), and catalase (Cat) genes in female brain blood vessels (BBV). Results are presented as relative expression of gene 
normalized to hypoxanthine-guanine phosphoribosyltransferase as a reference gene and summarized as arithmetic mean ± SD (two-
way AnoVA)
Female BBV Cu/Zn Sod* MnSod† EC-Sod‡ Gpx1§ Gpx4II Cat¶
Control 0.39 ± 0.12 (N = 6) 0.55 ± 0.19 (N = 6) 0.59 ± 0.33 (N = 6) 1.77 ± 0.70 (N = 6) 0.69 ± 0.46 (N = 6) 0.85 ± 0.26 (N = 6)
Carbohydrate- and 
fat-rich diet (HSHFD)
0.21 ± 0.15 (N = 6) 0.02 ± 0.003** (N = 4)0.05 ± 0.04†† (N = 8)0.09 ± 0.08** (N = 6) 0.06 ± 0.03††II II (N = 8) 0.82 ± 0.36 (N = 4)
HSHFD+metformin 0.33 ± 0.22 (N = 4) 0.07 ± 0.05** (N = 4) 0.04 ± 0.02†† (N = 6)0.74 ± 0.62**‡‡ (N = 4)0.07 ± 0.03††II II (N = 7) 0.92 ± 0.42 (N = 4)
HSHFD+liraglutide 0.49 ± 0.29 (N = 4) 0.13 ± 0.10** (N = 4) 0.11 ± 0.07 (N = 5) 0.91 ± 0.33**‡‡ (N = 4)1.15 ± 0.73§§ (N = 5) 1.37 ± 0.56¶¶ (N = 5)
*Cu/Zn Sod (P = 0.207, F = 1.607).
†MnSod (P = 0.0011, F = 6.819).
‡EC-Sod (P = 0.494, F = 0.8142).
§Gpx1 (P = 0.0023, F = 5.935).
IIGpx4 (P = 0.0002, F = 8.314).
¶Cat (P = 0.0459, F = 2.982).
**HSHFD; HSHFD+metformin; HSHFD+liraglutide vs control (MnSod P < 0.001), Bonferroni post hoc test, P < 0.05.
††HSHFD; HSHFD+metformin vs control (EC-Sod P < 0.05; Gpx4 P < 0.05), Bonferroni post hoc test, P < 0.05.
‡‡HSHFD+metformin; HSHFD+liraglutide vs HSHFD (EC-Sod P < 0.05), Bonferroni post hoc test, P < 0.05.
§§HSHFD+liraglutide vs control (Gpx4 P < 0.05).
II IIHSHFD+metformin; HSHFD vs HSHFD+liraglutide (Gpx4 P < 0.001).
¶¶HSHFD+liraglutide vs control (Cat P < 0.05).
tABlE 3. Relative expression of superoxide dismutase isoforms (Cu/Zn Sod, Mn Sod, and EC Sod), glutathione peroxidase 1 and 4 
(Gpx1, Gpx4), and catalase (Cat) genes in male aortas. Results are presented as relative expression of gene normalized to hypoxan-
thine-guanine phosphoribosyltransferase as a reference gene and summarized as arithmetic mean ± SD (two-way AnoVA)
Male aortas Cu/Zn Sod* MnSod† EC-Sod‡ Gpx1§ Gpx4II Cat¶
Control 0.57 ± 0.62 (N = 5) 0.10 ± 0.09 (N = 5) 0.72 ± 0.80 (N = 4) 0.91 ± 0.65 (N = 5) 0.76 ± 0.53 (N = 6) 1.22 ± 0.67 (N = 5)
Carbohydrate- and 
fat-rich diet (HSHFD)
0.34 ± 0.23 (N = 6) 0.08 ± 0.04 (N = 5) 0.37 ± 0.27 (N = 5) 0.21 ± 0.24†† (N = 5) 0.56 ± 0.49 (N = 6) 0.56 ± 0.36 (N = 4)
HSHFD+metformin 0.69 ± 0.61 (N = 7) 0.10 ± 0.12 (N = 7) 0.08 ± 0.06** (N = 7) 0.33 ± 0.47†† (N = 7) 0.31 ± 0.25 (N = 8) 0.56 ± 0.48 (N = 7)
HSHFD+liraglutide 0.55 ± 0.37 (N = 7) 0.21 ± 0.24 (N = 6) 0.49 ± 0.57 (N = 5) 0.62 ± 0.78 (N = 5) 0.92 ± 0.84‡‡ (N = 6) 0.97 ± 0.93 (N = 5)
*Cu/Zn Sod (p=0.1026, F=2.22).
†MnSod (P = 0.7179, F = 0.4513).
‡EC-Sod (P = 0.2289, F = 1.512).
§Gpx1 (P = 0.2512, F = 1.426).
IIGpx4 (P = 0.5166, F = 07716).
¶Cat(P < 0.0001, F = 78.42).
**HSHFD+metformin vs control (EC-Sod P < 0.05), Bonferroni post hoc test, P < 0.05.
††HSHFD+metformin, HSHFD vs control (Gpx1 P < 0.05), Bonferroni post hoc test, P < 0.05.
‡‡HSHFD+metformin vs HSHFD+liraglutide (Gpx4 P < 0.05), Bonferroni post hoc test, P < 0.05.
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Serum levels of antioxidant enzymes activity
Serum SOD, GPx, and CAT activity did not differ significant-
ly among female groups. Within male groups, SOD activity 
was significantly decreased in the HSHFD+metformin group 
compared with other groups (P < 0.001). GPx activity in the 
HSHFD+liraglutide male group was significantly decreased 
compared with the control and HSHFD groups (P < 0.05) 
and in the HSHFD+metformin group compared with con-
trols (P < 0.001). CAT activity in the HSHFD+liraglutide male 
group was significantly increased compared with the 
HSHFD+metformin male group (P < 0.01) and decreased 
compared with the control male group (P < 0.001). CAT ac-
tivity in the HSHFD (P < 0.001) and HSHFD+metformin male 
group (P < 0.001) was significantly decreased compared 
with the control male group (Figure 3).
SOD and CAT activities were significantly increased 
in the male control (P < 0.01), HSHFD (P < 0.01), and 
HSHFD+liraglutide (P < 0.01) group compared with the 
corresponding female groups (Figure 3A and 3C). GPx1 
activity in the male group was significantly increased 
in the control (P < 0.001), HSHFD group (P < 0.001), and 
HSHFD+metformin group (P < 0.001) compared with the 
corresponding female groups (Figure 3B).
oxidative stress and antioxidative capacity in serum 
samples
Oxidative stress (TBARS) level did not change significant-
ly between groups or sexes (Figure 4A). Antioxidant ca-
pacity (FRAP values) was significantly increased in the 
HSHFD+liraglutide group (female P < 0.01; male P < 0.05) 
compared with the HSHFD group in both sexes. The level 
of antioxidant capacity in all studied groups did not signifi-
cantly differ between the sexes (Figure 4B).
DISCuSSIon
The main findings of the study performed in male and fe-
male rats: a) HSHFD diet increased body weight in both 
tABlE 5. Relative expression of superoxide dismutase isoforms (Cu/Zn Sod, Mn Sod, and EC Sod), glutathione peroxidase 1 and 4 (EC-
Sod, Gpx4), and catalase (Cat) genes in male brain blood vessels (BBV). Results are presented as relative expression of gene normal-
ized to hypoxanthine-guanine phosphoribosyltransferase as a reference gene and summarized as arithmetic mean ± SD (two-way 
AnoVA)
Male BBV Cu/Zn Sod* MnSod† EC-Sod‡ Gpx1§ Gpx4II Cat¶
Control 0.78 ± 0.06** (N = 5) 0.70 ± 0.55 (N = 5) 1.13 ± 0.95 (N = 5) 0.73 ± 0.11 (N = 5) 0.75 ± 0.27 (N = 5) 0.92 ± 0.11 (N = 5)
Carbohydrate- and 
fat-rich diet (HSHFD)
0.55 ± 0.63 (N = 5) 0.30 ± 0.16†† (N = 6) 0.14 ± 0.09‡‡ (N = 5) 0.39 ± 0.30 (N = 6) 0.17 ± 0.05‡‡ (N = 5) 0.48 ± 0.47 (N = 5)
HSHFD+metformin 0.60 ± 0.06** (N = 5) 0.27 ± 0.68†† (N = 5) 0.27 ± 0.27‡‡ (N = 6) 0.50 ± 0.13 (N = 6) 0.21 ± 0.14‡‡ (N = 6) 0.51 ± 0.11 (N = 5)
HSHFD+liraglutide 0.62 ± 0.20** (N = 5) 0.60 ± 0.06 (N = 6) 0.36 ± 0.12‡‡ (N = 5) 0.62 ± 0.26 (N = 5) 0.20 ± 0.05‡‡ (N = 6) 0.54 ± 0.26 (N = 6)
*Cu/Zn Sod (P = 0.207, F = 1.607).
†MnSod (P = 0.0011, F = 6.819).
‡EC-Sod (P = 0.494, F = 0.8142).
§Gpx1 (P = 0.0023, F = 5.935).
IIGpx4 (P = 0.0002, F = 8.314).
¶Cat (P = 0.0459, F = 2.982).
**P < 0.05 HSHFD vs control; HSHFD+metformin; HSHFD+liraglutide (Cu/Zn Sod P < 0.05), Bonferroni post hoc test, P < 0.05.
††P < 0.05 HSHFD+liraglutide vs HSHFD; HSHFD+metformin (MnSod P < 0.01), Bonferroni post hoc test, P < 0.05.
‡‡P < 0.05 HSHFD; HSHFD+metformin; HSHFD+liraglutide vs control (EC-Sod P < 0.05, Gpx4 P < 0.05), Bonferroni post hoc test, P < 0.05.
FIGuRE 2. Blood glucose values (mmol/l) at the end of the 
protocol for all test groups of female and male rats. this 
part of the experiment included 28 female rats (control 
group n = 6, carbohydrate- and fat-rich diet [HSHFD] n = 8, 
HSHFD+metformin group n = 7, HSHFD+liraglutide group 
n = 7) and 29 male rats (control group n = 7, HSHFD group 
n = 6, HSHFD+metformin group n = 8, HSHFD+liraglutide 
group n = 8). Data are presented as arithmetic mean ± stan-
dard deviation (SD) (two-way AnoVA P = 0.5419, F = 0.7251)
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sexes; b) liraglutide treatment prevented the increase in 
body weight induced by HSHFD, while this effect was not 
observed with metformin treatment; c) liraglutide treat-
ment significantly increased antioxidative capacity com-
pared with the HSHFD group in both sexes; d) the activity 
of antioxidative enzymes was generally lower in females 
than in males; e) in male groups, HSFHD with or without 
antidiabetic therapy significantly lowered the activity of 
antioxidant enzymes compared with the control group; f ) 
changes of antioxidative enzymes’ gene expression were 
more prominent in microvessels. All together, these results 
support the hypothesis that weight gain due to sugar- and 
fat-rich diet is crucial in developing oxidative stress due to 
inhibited antioxidative protective mechanisms.
GLP-1 receptors are found throughout the gastrointestinal 
tract, cardiomyocytes, vasculature, and the sinoatrial node 
(31-33). Newly developed agents acting through incretin 
hormones promote weight loss, in contrast to some oral 
antidiabetic agents (such as insulin secretagogues – sul-
fonylureas and meglitinides), thiazolidinediones, and insu-
lin (34-36), which are associated with an increase in body 
weight (37). Our results are in concordance with these ob-
servations, showing that liraglutide prevented weight gain 
FIGuRE 3. Comparison of serum antioxidative enzymes activities (SoD (A), GPx (B), and CAt (C)) between the sexes. the num-
ber of female samples for the measurement of serum SoD (control group n = 5, carbohydrate- and fat-rich diet [HSHFD] n = 7, 
HSHFD+metformin group n = 7, HSHFD+liraglutide group n = 4), GPx (control group n = 6, HSHFD n = 8, HSHFD+metformin 
group n = 7, HSHFD+liraglutide group n = 5), and CAt activity (control group n = 5, HSHFD n = 6, HSHFD+metformin group n = 6, 
HSHFD+liraglutide group n = 3). the number of male samples for the measurement of SoD (control group n = 6, HSHFD n = 6, 
HSHFD+metformin group n = 8, HSHFD+liraglutide group n = 8), GPx (control group n = 7, HSHFD n = 5, HSHFD+metformin 
group n = 8, HSHFD+liraglutide group n = 8), and CAt activity (control group n = 7, HSHFD n = 4, HSHFD+metformin group n = 6, 
HSHFD+liraglutide group n = 6). Data are presented as arithmetic mean ± standard deviation (SD) (two-way AnoVA: SoD P = 0.0013, 
F = 6.201; GPx P = 0.0004, F = 7.325; CAt P = 0.0003, F = 8.274).
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in animals fed with HSHFD compared with other obese 
groups of both sexes. These protective effects were not 
observed with metformin. Previous studies also found that 
patients with severe insulin resistance lost significantly 
more weight compared with insulin-sensitive patients (38). 
Additionally, our results showed that HSHFD increased glu-
cose levels in neither of the sexes, which further confirms 
the metformin-related results. The similar blood glucose 
concentration among the groups observed in the present 
study is not in accordance with the results of a pre-diabe-
tes rat model by Sheng et al (39). The authors showed that 
high-fat diet had a greater effect on glucose level and that 
high-sugar diet had a greater effect on blood triacylglycer-
ol concentrations (39). The differences can be explained by 
a different fat and carbohydrate food content used in the 
two studies – while Sheng et al used food containing 20% 
fat and 20% of carbohydrates, the food in our study con-
tained 56% carbohydrates and 12% of crude fat.
ROS, generated at sites of inflammation and damage, 
may cause cell damage and death. In vasculature, oxida-
tive stress increases vascular endothelial permeability and 
promotes leukocyte adhesion (12). Our study did not find 
significantly increased serum TBARS levels, but it did ob-
serve an increased antioxidant capacity, showing a signifi-
cant positive role of liraglutide in increasing the antioxida-
tive status (19). Furthermore, liraglutide therapy and body 
weight reduction significantly increased the antioxidant 
capacity (FRAP values) compared with the HSHFD group 
in both sexes, which suggests an important antioxidant ef-
fect of liraglutide.
Although antioxidant enzyme activity in both sexes 
changed depending on the dietary protocol and therapy, 
it was lower in female groups. Enzyme activity was also 
modulated by liraglutide and metformin treatment. Indi-
vidual studies examining sex differences and changes of 
antioxidant enzymes activity have shown that older male 
mice had a weakened link among three antioxidant en-
zymes (SOD, GPx, and CAT), regardless of lipid peroxidation 
concentration (40). However, in the liver and brain of old-
er female mice, the cooperation between antioxidant en-
zymes was more coherent with increased lipid peroxida-
tion concentration, which might explain why old females 
are better protected from oxidative stress than males (40). 
Our results suggest greater differences in enzyme activi-
ties among male groups, while antioxidative enzymes in 
female groups were not affected by dietary and pharma-
cological protocols. These findings suggest a more stable 
antioxidant status among females, which might explain 
their lower enzyme activity.
A limitation of our study was that the experimental design 
prevented us from performing a glucose tolerance test. 
FIGuRE 4. Indicators of oxidative stress. Comparison of thiobarbituric acid reactive substances (tBARS) values (A) and ferric reduc-
ing ability of plasma (FRAP) (B) between the sexes. the number of samples for tBARS per group: female groups (control n = 5, 
carbohydrate- and fat-rich diet [HSHFD] n = 7, HSHFD+metformin n = 7, HSHFD+liraglutide n = 5) and male groups (control n = 6, 
HSHFD n = 6, HSHFD+metformin n = 8, HSHFD+liraglutide n = 8) and for FRAP measurements in female groups (control n = 5, HSHFD 
n = 7, HSHFD+metformin n = 7, HSHFD+liraglutide n = 5) and male groups (control n = 6, HSHFD n = 6, HSHFD+metformin n = 7, 
HSHFD+liraglutide n = 8). Data are presented as arithmetic mean ± standard deviation (SD) (two-way AnoVA: tBARS P = 0.9880, 
F = 0.04305; FRAP P = 0.9493, F = 0.1175).cx
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Future studies could benefit from performing this test to 
establish a period of insulin resistance and to determine 
whether increased oxidative stress occurs before or after 
insulin resistance. Because of the strong impact of obesity 
and diabetes on the blood vessels reactivity (41-43) and 
endothelium-dependent responses (44,45), we examined 
the expression of antioxidant enzymes, which act as the 
first line of defense from high oxidative stress. The expres-
sion of antioxidant enzymes differed depending on the 
type of blood vessels and sex. Furthermore, it changed 
more significantly in the BBV of both sexes. A significant 
difference between the sexes in the gene expression of 
antioxidant enzymes was already observed between the 
control groups without treatment. HSHFD diet mostly af-
fected MnSOD level only in the BBV. Higher expression 
of significant genes in the male than in the female group 
might explain higher enzyme activity in males.
In conclusion, we observed sex-related differences in oxi-
dative stress level. Although we cannot determine which 
sex balances antioxidant status better based on gene ex-
pression and the level of antioxidant capacity alone, an-
tioxidant enzymes activity in the female groups did not 
change significantly, indicating a more stable antioxida-
tive status. The observed changes in oxidative status may 
be related to increased body weight, treatment prevent-
ing body weight gain, and oxidative stress increase. Li-
raglutide was more effective than metformin in regulat-
ing oxidative stress. The observed changes were more 
prominent in the microcirculation, supporting the obser-
vations of endothelial dysfunction in pre-diabetes and 
diabetes.
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